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The C282Y mutation of HFE accounts for the majority of cases of the iron overload disease Hereditary Hemochromatosis (HH).
The conformational changes introduced by this mutation impair the HFE association with β2-microglobulin (β2m) and the cell
surface expression of the protein: with two major consequences. From a functional perspective, the ability of HFE to bind to
transferrin receptors 1 and 2 is lost in the C282Y mutant, thus aﬀecting hepcidin regulation. Also due to the faulty assembly
with β2m, HFE-C282Y molecules remain in the endoplasmic reticulum (ER) as aggregates that undergo proteasomal degradation
and activate an Unfolded Protein Response (UPR). UPR activation, regardless of the ER stress stimuli, was shown to reshape the
expression proﬁle of iron-related genes and to decrease MHC-I cell surface expression. The possibility of a HFE-C282Y-mediated
interplay between the UPR and iron homeostasis inﬂuencing disease progression and the clinical heterogeneity among C282Y
carriers is discussed. The responsiveness of the ER chaperone calreticulin to both ER and iron-induced oxidative stresses, and its
correlation with HH patients’ phenotype, reinforce the interest of dissecting the UPR signaling/iron metabolism crosstalk and
points to the potential clinical value of use of pharmacological chaperones in HFE-HH.
1.Introduction
Occupying a central position in the secretory route, the
endoplasmic reticulum (ER) performs a vast array of func-
tions that includes the biosynthesis, folding, assembly, and
posttranslational modiﬁcation of secretory and membrane-
targeted proteins [1] .T h ea c c u r a c yo ft h i sv a r i e t yo fp r o -
cesses relies on specialized luminal conditions, thoroughly
maintained by stringent quality control mechanisms [2].
Despite the sophistication of such mechanisms, certain
physiological states and exogenous stimuli can compromise
this optimal folding environment and are generally referred
to as ER stress [3].
The realization that there is a functional intersection
between ER stress and iron metabolism emerged ﬁrst from
studies of the genetic disorder of iron overload, Hereditary
Hemochromatosis (HH) type 1. Arising from a defective
regulation of iron absorption, HH is intrinsically related
to the gene HFE [4]. The product of this gene shares
structural homology to a major histocompatibility complex
class I (MHC-I) protein, requiring association with β2-
microglobulin (β2m) for cell surface expression [5, 6]. In
contrast to conventional MHC-I molecules, HFE is unable to
bindpeptidesandhasnotbeenimplicatedinantigenpresen-
tation functions [6]. Instead, the HFE-β2m heterodimer was
shown to bind transferrin receptor (TfR)1, thus competing
foritsinteractionwithdiferrictransferrin[7,8].Thebinding
capacity of HFE was later extended to TfR2 [9]. C282Y
and H63D are the two point mutations of HFE commonly
underlying HH [5]. The former, resulting from a G-A
transition that replaces the amino acid cysteine by tyrosine
at position 282, is carried by the majority of HH patients
(>85%), while the H63D, consisting in a C-G transition that
determines a histidine to aspartate substitution at position
63, acquires clinical signiﬁcance in C282Y/H63D compound
heterozygotes [10, 11].
The surprise caused by the discovery of a MHC-I-
like protein partaking in iron homeostasis was diluted by
previous research, fertile in reports describing immuno-
logical abnormalities in HH patients. Accordingly, higher2 Biochemistry Research International
CD4+/CD8+ ratios[12],laterattributedtodefectivenumbers
of CD8+ T cells [13], were consistently found in HH subjects
in comparison to control individuals. Complementing these
data, increased clinical severity of the disease was observed
in the context of a lower CD8+ T lymphocyte pool [14].
Discrepancies at the functional level were likewise revealed,
with CD8+ T cells from HH patients exhibiting impaired
cytotoxic and CD8-p56lck activities when compared to
healthy controls [15, 16]. A glimpse for the structural
homology with MHC-I molecules was also provided by the
spontaneous iron overload phenotype developed in β2m−/−
mice [17].
The elucidation of the genetic background of HH, in
concert with the rapid adoption of HFE mutation testing
in clinical practice, soon revealed a poor penetrance of the
disease in C282Y carriers [18]. A remarkable phenotypic
heterogeneity among patients was noticed as well [19],
suggesting the existence of additional factors modifying this
genetically determined disorder. Modiﬁers of the clinical and
immunological traits of HH have been actively pursued,
namely, genetic ones [20]. In light of the recent ﬁndings,
the Unfolded Protein Response (UPR) has emerged as a
promising candidate.
2. The C282Y Mutation andthe UPR
By blocking the formation of a disulphide bond in the α3
domain of HFE, the C282Y mutation prevents the assembly
withβ2m[10,21].Asaconsequence,themutantproteinfails
to progress through the secretory pathway and remains in
the ER as high molecular weight aggregates [10, 22, 23] that
undergo proteasome-dependent degradation [10]. Besides
the presence of such intracellular aggregates, cells expressing
the C282Y mutant version of HFE also display decreased
surface expression of MHC-I molecules [24]. Seeking the
molecular details underlying this observation and inspired
by the ER retention of the C282Y mutant, de Almeida and
coworkers established the UPR as a mechanism mediating
the HFE/MHC-I crosstalk [25]. Both the UPR/MHC-I
interplay and the ability of the C282Y faulty HFE to elicit
UPR activation were later independently conﬁrmed [26, 27].
UPR is the designation of the specialized signaling
circuits developed by cells to counteract the luminal accu-
mulation of misfolded client proteins and rebalance the
load/capacity ratio of the ER threatened by physiological
states and exogenous conditions as diverse as potent secre-
tory activity, disruption of Ca2+ stores, alteration of redox
status, energy/nutrient deprivation, expression of mutant
substrates, and viral infection [28, 29]. Tailored to restore
ER homeostasis, the UPR combines multiple synergistic
strategies that encompass global suppression of protein
synthesis and translocation into the ER, transcriptional
inductionofERchaperonesandfoldasestofacetheincreased
folding demands, and improvement of the ER-associated
degradation (ERAD) machinery to bolster the clearance of
irreparably unfolded proteins [3, 30]. If the prosurvival
attempts are exhausted and ER damage prevails, UPR-
induced proapoptotic programs are executed [31].
In mammalian cells, three ER-resident transmembrane
proteins operate as proximal sensors and deﬁne the major
UPR signaling pathways: double-stranded RNA-dependent
protein kinase-like ER kinase (PERK), inositol-requiring
enzyme (IRE)1, and activating transcription factor (ATF)6
[3, 30]. Notwithstanding this diversity, association with
the ER-resident chaperone immunoglobulin heavy chain-
binding protein (BiP) is proposed as a common regulator
of the ER transducers. Under unstressed conditions, BiP
binds the luminal domains of all sensors, rendering them
inactive. As unfoldedproteins congestthe ER, BiP is compet-
itively titrated away, allowing the PERK-, IRE1-, and ATF6-
dependent cascades to proceed [32, 33]. Alternative models
of sensing have been presented as well. It was suggested,
for example, that the MHC-like groove displayed by yeast
IRE1 directly detects and binds misfolded clients in the ER
lumen, which would contribute to IRE1 activation [34]. The
groove dimensions in the related human protein, too narrow
to accommodate peptides, have weakened the likelihood
of this mechanism, however [35]. The two perspectives
were recently reconciled by a model postulating that direct
interaction with unfolded proteins is required for IRE1
a c t i v a t i o n ,w h e r e a sB i Ps e r v e sb o t ha sb u ﬀer and timer of
UPR activity [36].
Encouraged by the misfolding nature of the C282Y HFE
proteinandthesubsequentUPRactivation,categorizationof
HH as a conformational disorder has been claimed [37, 38].
A reasonable explanation for the aforementioned genotype-
phenotypeinconsistenciesamongstHHpatientscouldthere-
fore rely, at least in part, on dissimilar individual abilities
t om o u n ta na p p r o p r i a t ep r o t e c t i v er e s p o n s et o w a r d st h e
C282Y mutant client. Albeit attractive, this hypothesis is
far from consensual. One argument militating against it
relates with the low tissue levels of HFE expression, recently
estimated below 0.53 nmol/g of total protein in human liver
[39]. Nonetheless, and despite some controversial data [40],
increased hepatic mRNA expression of HFE was reported in
iron-supplemented mice [41, 42], a trend also recapitulated
by microglia-derived cells subjected to stressor agents and
serum deprivation [43]. Accordingly, one could envisage
a scenario in which the basally innocuous HFE pool may
accumulate to levels that clog the ER with the C282Y
misfolded variant as iron overload progresses in HH, thus
favoring ER stress conditions. Whether and how this vicious
cycle-based model inﬂuences the in vivo pathophysiology of
HFE-linked HH deﬁnitely deserves assessment.
3. The UPR CrosstalkwithIronMetabolism
3.1. Expression Proﬁle of Iron-Related Genes. Originally
described as a check-and-balance program focused on the
recovery of stress-corrupted ER folding homeostasis, the
boundaries of UPR have been steadily broadened to cell dif-
ferentiation, metabolic and inﬂammatory processes [44–46].
Suggestive evidence for an intersection with iron metabolism
wasﬁrstp r o vid edfo rtuit ousl yb ydiﬀerentialgeneexpression
screenings. Two such examples are the increased transcript
levelsoftheERchaperonescalreticulin(CRT)andBiPfoundBiochemistry Research International 3
in iron-burdened astrocytoma cells [47] and the transferrin
gene downmodulation reported in stable transfectants of
the stress-inducible transcription factor CCAAT/enhancer-
binding protein (C/EBP) homologous protein (CHOP) [48].
Likewise, proteomic analysis revealed increased hepatic BiP
expression in dietary iron-loaded mice [49], although in
vitro studies using the human hepatoma HepG2 cell line
have failed to conﬁrm this result (Pinto et al., unpublished
data). Despite all these cues, the interplay of UPR and iron
homeostasis has remained a hitherto unexplored ﬁeld.
By exposing a hepatocyte-derived cell line to chemical
agents impairing disulphide bond formation (dithiothreitol
andhomocysteine)inERclientproteins,werecentlydemon-
strated that ongoing ER stress signiﬁcantly reshapes the
expression proﬁle of iron-related genes, namely, hepcidin,
ferroportin, and ferritin H. Using this experimental model,
the molecular mechanism behind the biphasic modulation
of hepcidin was also deciphered, with the nuclear factors
C/EBPα and CHOP being implicated [50]. The interplay
between iron metabolism and the UPR signaling pathways
was independently corroborated by Vecchi et al. that,
after stressing hepatoma-derived cells with the ER-to-Golgi
transport inhibitor brefeldin A, calcium ionophore A23187
and tunicamycin, reported increased levels of hepcidin tran-
scripts, a pattern also detected in the liver of tunicamycin-
treated mice. The stimulation of hepcidin was attributed
to cAMP response element-binding protein H (CREBH)-
dependent activation of its promoter [51]. The mechanisms
proposed by the two studies [50, 51] for hepcidin induction
under stress scenarios are not incompatible and could
conceivably coexist.
3.2. Calreticulin, a Chaperone Related to Clinical Expression
of Iron Overload. As discussed earlier, UPR activation is
characterizedbytheinductionofseveralERstress-responsive
proteins. One of these molecules is CRT, a 46kDa ER-
resident lectin chaperone with Ca2+-buﬀering capacity,
speciﬁcallydevotedtothefoldingofalargefractionofclients
traversing the secretory route, glycoproteins.
In addition to the chaperone function, CRT is involved
in protection from stress usually not included in the UPR-
related ER stress category. CRT synthesis is induced by heat
shock [52–54]a n dh e a v ym e t a l s[ 53], which has recently
drawn attention to the role of this protein in protection
from oxidative stress [55]. CRT, together with the other ER
chaperone BiP, protected renal epithelial cells against lipid
peroxidation induced by the prooxidant reagent tert-butyl
hydroperoxide [56]. Production of the antioxidant nitric
oxide leads to overexpression of CRT in pancreatic beta
cells [57]. Also, hypoxic conditions, such as those found in
wounds, can lead to overexpression of CRT by 2 to 3 folds,
with a 7-fold increase observed in response to H2O2-induced
oxidative stress during rat cardiomyocyte injury [58].
Ap o s s i b l ep r o t e c t i v er o l ef o rC R Tw a sf o u n di n
C282Y homozygous HH patients, in which the iron-induced
oxidative stress and an UPR triggered by the unfolded
C282Y-mutated HFE protein coexists. In this study [59], a
negative association was found between the levels of CRT
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Figure 1: CRT expression and HH-related symptoms. CRT mRNA
expression in PBMCs from HFE C282Y homozygous patients. Each
bar represents an individual subject, ordered by CRT level and
divided according to the presence (light blue bars) or absence (dark
blue bars) of cirrhosis/ﬁbrosis (CIRR/FIB), modiﬁed by Porto from
original data from Pinto et al., 2008 [59].
in peripheral blood mononuclear cells (PBMCs) and the
severity of HH clinical manifestations (Figure 1). Although
the mechanism underlying the variability in CRT expression
among HH patients has not been elucidated, the ﬁnding of a
positive association between CRT mRNA levels, BiP expres-
sion, and numbers of monocytes (the PBMC population
with the highest HFE expression) favors the interpretation
that CRT expression is being modulated by the UPR in
PBMCs from C282Y+/+.
The involvement of CRT in cellular protection from
oxidative stress is possibly the mechanism underlying the
changes in CRT expression in response to increased intra-
cellular iron levels observed in colorectal adenocarcinoma
(Caco-2) and hepatocarcinoma (HepG2) cell lines [59,
60]. In the N´ u˜ nez et al. study [60], the iron-induced
increase in CRT expression was eﬀectively blocked by the
antioxidant quercetin, whereas Pinto et al. showed, using
both over-expression and siRNA-mediated silencing, that
CRT upregulation is necessary to prevent iron-induced ROS
accumulation [59].
How could CRT exert its role in the protection of the
cell against iron-induced oxidative stress? An answer might
be given by mobilferrin, a cytosolic protein involved in
the intracellular transport of iron during intestinal iron
absorption [61]. Rat mobilferrin and CRT share 100%
homology in the amino-terminal amino acid sequence; both
proteins have the same apparent molecular weight and
isoelectric point, and the antibodies raised against one of
the proteins cross-react with the other [62]. Mobilferrin is
thus considered to be an isoform of CRT, although further
studies are needed to conﬁrm this hypothesis. The increase
in CRT/mobilferrin in a situation of augmented intracellular
iron levels (Figure 2) could be a response of the cell to
the need for more iron-binding capacity, to ameliorate the
iron-induced oxidative stress. In view of the presence of
CRT in several intracellular (and extracellular) locations,
this role could take place in a variety of compartments,4 Biochemistry Research International
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Figure 2: Regulation of CRT mRNA by iron. Linear regression
analysis of the correlation between intracellular iron levels (3
μM ferric nitrilotriacetate (55Fe–NTA) were used as iron source),
and CRT mRNA pools in HepG2 cells overexpressing the WT or
mutated (C282Y or H63D) HFE variants (HepG2 cells transfected
withtheemptypcDNA3vectorwereusedasnegativecontrol).Each
dot represents the average of one experiment with three replicates.
r = 0.97; P<. 001. Inner dashed curves represent 95% conﬁdence
intervals for the mean value of CRT at any selected CPM value.
Outer dashed lines are 95% prediction limits for new observations.
Modiﬁed from Pinto et al., 2008 [59].
where the need for iron buﬀering would be present. One
such compartment is the nucleus, where the presence of
hydroxyl radicals generates a whole series of DNA damage,
namely, single- or double-strand breaks, abasic sites and
base and sugar lesions [63, 64]. Interestingly, over the last
two decades, several studies have reported the presence of
ferritin, the main iron-storage protein, in cell nuclei [65].
The earliest observations of nuclear ferritin were made in
mice hepatocytes following iron overload [66]. Later, the
presenceofferritininthenucleuswasfoundtocorrelatewith
higher resistance to UV and H2O2-induced DNA damage
on corneal epithelial cells [67, 68], suggesting the need for
protection from iron-induced oxidative stress in the nucleus.
CRT participation in the response to oxidative stress
may be a component of the broader involvement of
the ER in cellular protection from a varied category of
insults, namely those involving the iron overload toxicity.
The predominant location of CRT and other ER proteins
within the hyperoxic environment of the ER increases their
susceptibility to oxidative damage [69], which, along with
posttranslational modiﬁcations, can aﬀect both the function
and cellular location of these proteins [70]. All concurrent
hypothesesagreethatoxidativestress-inducedERstressleads
to extracellular release of CRT and other ER proteins. The
mechanisms involved in the translocation of the protein to
the extracellular compartment are not yet fully understood,
although they seem to involve triggering of apoptotic cell
regulatory proteins (caspases, Bap31, Bax activation), an
ER stress response leading to the phosphorylation of the
eukaryotic initiation factor eIF2α and active exocytosis [71–
74].
3.3. Calreticulin, at the Crossroads of MHC-I Expression
and Iron Overload. Impaired cell surface expression of
MHC-I molecules is another feature found in C282Y+/+
hemochromatosis patients besides iron overload. In view of
the UPR/MHC-I crosstalk revealed in recent years [25, 26],
together with the iron burden developed by β2m and MHC-I
KO murine models [17, 75], the chaperone activity of CRT
might gain a renewed relevance in the context of MHC-
I assembly. The process takes place in the ER with the
assistance of a number of chaperones and folding factors,
which include CRT. The complex to be assembled consists
of a glycosylated heavy chain, a β2m molecule, and a peptide.
Peptide loading of MHC-I molecules is the ﬁnal step of an
intricatepathwaythatresultsfromtheadaptationofaquality
control cycle that regulates the folding of conventional
glycoproteins [76]. The complex responsible for peptide
loading comprises the peptide transporter TAP (transporter
associated with antigen processing), ERp57, CRT, calnexin
(CANX), and tapasin (TAPBP, TAP-binding protein) [77,
78]. Both CRT and CANX promote the assembly of MHC-I
and retain incompletely assembled complexes in the ER [78].
CRT binds to a monoglucosylated N-linked glycan at Asn86
of the MHC-I heavy chain with a dissociation constant of
approximately 1μM[ 79], following CANX release.
The importance of CRT in MHC-I processing is illus-
trated by the suboptimal MHC-I assembly in CRT KO cells
[80], with MHC-I expression and stability at the cell surface
being rescued by the reintroduction of a lectin-deﬁcient
CRT mutant [81]. Although the mechanisms underlying
the involvement of the MHC-I in iron metabolism remain
unclear, the CRT role in MHC-I assembly/expression may, at
least in part, explain the protective function of this protein in
iron overload [59].
4. The UPR CrosstalkwithIronMetabolism:
PutativePhysiologicalSigniﬁcance
The central regulator of iron homeostasis is hepcidin, a 25-
residue peptide hormone. Mainly secreted by hepatocytes
[82], hepcidin binds to the membrane iron exporter ferro-
portin, triggering its internalization and lysosomal degrada-
tion [83]. Iron egress from enterocytes and macrophages is
therefore inhibited, ultimately restricting the availability of
the biometal in circulation. The pleiotropic nature of hep-
cidin arises from its responsiveness to iron, inﬂammation,
anemia, and hypoxia [84, 85]. Hepcidin is physiologically
stimulated by increased iron stores and inﬂammation, with
the converse occurring in the remaining conditions. This
versatility is mirrored by the array of signaling pathways
coordinating hepcidin transcription as yet identiﬁed [86–
91], now extended to the ER stress chain of events.
AsystemicimpactoftheUPRhasbeendisclosedthrough
the connection to insulin secretion and peripheral resistance
[92, 93], glucose homeostasis [94], and inﬂammation [95].
With the UPR-induced hepcidin modulation [50, 51], a newBiochemistry Research International 5
item can be coupled to this picture. By limiting duodenal
iron absorption, hepcidin upregulation in this context may
be part of a protective “strategy” to evade extra sources of
stress, as those associated with iron-generated ROS. In line
with hepcidin’s antimicrobial role [82], consequences on the
innate immunity are expected as well, thereby furthering
the scope of the recently uncovered ER stress-mediated
inﬂammatory responses [46, 96].
Besides the systemic impact underlined by hepcidin,
repercussions of UPR activation are also manifested at
the cellular iron metabolism level, as suggested by the
modulationofferroportinandferritinHexpressionimposed
by ER insults [50]. The mRNA enrichment of both genes
in cells enduring ER stress may reﬂect an attempt to
circumvent intracellular deposition of free iron either via its
sequestration or export, respectively.
5. The UPR CrosstalkwithIronMetabolism:
A Linkto Pathological Conditions
Building evidence has coupled the ER stress response
circuitries to multiple pathologies, namely diabetes, obesity,
and neurodegeneration [97–99]. Apart from the above-
described connection with HFE-linked HH, the novel asso-
ciation between ER stress and iron homeostasis may prove
useful in furthering the understanding of neurodegenerative
processes.Infact,ironaccumulationinaﬀectedbrainregions
is a commonality of various neuropathologies, including
Alzheimer’sdisease(AD)andParkinson’sdisease(PD)[100].
Regardless of the yet uncertain mechanisms driving such
deposition, the signiﬁcance of inherent oxidative stress to
neuronal damage has been increasingly recognized [101].
Belonging to the class of conformational disorders, protein
misfolding and aggregation are also hallmarks of both AD
and PD, probably potentiating neuronal cell death [99]. The
neurodegeneration ﬁeld may be therefore worth exploring
forthedialoguebetweenironhomeostasisandERstress.One
can conceive, for example, that the transcriptional reshaping
triggered by UPR activation takes part on the brain iron
imbalance observed in AD and PD.
Another foreseeable repercussion of these new ﬁndings
touches on the virus-iron metabolism-UPR deﬁned triad.
The ability of viruses to coopt the biochemical machineries
of host cells to mass replicate themselves is a longstanding
concept. One of the widely studied processes is the viral
interference with multiple steps of MHC-class I antigen
presentation route, likely evolved to elude immune surveil-
lance [102]. Because iron availability is critical for eﬃcient
proliferation, an additional subversive approach triggered by
viruses includes manipulation of host iron status. Despite
our still tangential understanding of this strategy, progress
has been made by demonstrating that TfR1 might be
e n g a g e di nt h ev i r a le n t r yp r o c e s s[ 103, 104]. Furthermore,
US2 and Nef proteins encoded in the genomes of human
cytomegalovirus (HCMV) and human immunodeﬁciency
virus (HIV)-1, respectively, were shown to down regulate
the cell surface expression of HFE [105, 106], presumably
withtheconsequenceofreplenishingintracellularironstores
and beneﬁt viral growth. Also supporting this interaction,
repressed hepcidin synthesis was attributed to hepatitis C
virus (HCV) infection [107]. The UPR, whose activation
has been proven in infected cells [108–110], emerges as
a plausible common denominator of the aforementioned
viral strategies. In fact, by exploiting the UPR pathways,
viruses might simultaneously: (i) guarantee ER expansion
to accommodate massive production of viral proteins, (ii)
impair MHC-class I presentation [25, 26], thus helping in
the immune evasion endeavor, and (iii) tune the activity of
hostproteinsinvolvedinironmetabolismtoensureadequate
supply of this biometal.
ThebiologicalrelevanceoftheUPR-inducedmodulation
of iron homeostasis in the context of neurodegeneration and
viral infection must be thoroughly characterized, warranting
promising research directions.
6. HH:A Candidatefor Pharmacological
Chaperone Therapy?
In light of the current paradigm, the iron-dependent tuning
of hepcidin is governed by the HFE/TfR1/TfR2 partnership
[88]. Due to compromised cell surface expression, the
C282Y variant of HFE fails to bind TfR1 or to stabilize
TfR2 according to the prevailing transferrin saturation
levels. Impairment of the adequate adjustment of hepcidin
levels causes parenchymal iron deposition, with associated
complications including cirrhosis, heart failure, diabetes,
and arthropathy [4]. This loss-of-function model, however,
challenges the identiﬁcation of novel regulatory mechanisms
mediated by the C282Y mutation, as those involving its ER
retention. In fact, to what extent misfolding events triggered
bytheC282YmutantinﬂuencethecourseofHFE-linkedHH
remains elusive.
The standard therapy for HH consists in periodic blood
withdrawals—phlebotomy—aimed at depleting excessive
iron stores [4]. Early initiation of treatment eﬃciently
prevents organ failure due to iron toxicity and restores
normal lifespan, although arthropathy barely improves
[111]. Nevertheless, the immunological anomalies reported
in HH patients are not solved by the blood-letting ther-
apy [16], supporting the existence of factors beyond iron
overload dictating such traits. The protective role against
oxidative stress recently attributed to CRT in HFE C282Y
stable transfectants, along with the negative correlation
between expression of this ER chaperone and the number
of clinical manifestations presented by HH subjects [59],
conveys the rationale for considering that pharmacologi-
cal chaperones might be useful in the context of HFE-
hemochromatosis.
The pharmacological manipulation of ER folding capac-
ity and quality control systems has merited particular
attentioninrecentyearsaspromisingtherapeuticstrategyfor
conformational disorders [112]. Relying on low-molecular-
weight compounds that stabilize native conformations and
compensate intrinsic folding deﬁcits, this approach may
limit aggregation episodes and/or rescue protein function
[113–116]. The endogenous bile acid taurine-conjugated6 Biochemistry Research International
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Figure 3: ER stressing iron homeostasis. Iron homeostasis (upper panel). Hepcidin is today thought to be the key regulator of iron
homeostasis. Lower hepcidin levels have been seen associated with progression of iron overload in Hereditary Hemochromatosis (HH).
HH is intrinsically related to the gene HFE and to a point mutation commonly known as C282Y replacing cysteine by tyrosine at position
282. A high proportion of HH patients are homozygous for the C282Y mutation. ER stress (lower panel). Studies by two separate groups
showed in recent years that the C282Y mutation in HFE provoked the activation of the Unfolded Protein Response (UPR) leading the two
groups to consider HH a conformational disorder. In addition, some clinical phenotypic heterogeneity reported in HH has been related
to variation in levels of mRNA expression of the endoplasmic reticulum (ER)-chaperone calreticulin (CRT). UPR activation has also been
shown by separate groups to aﬀect hepcidin gene expression. The intriguing eﬀect of the UPR on cell surface expression of MHC class I may
also contribute to the phenotypic heterogeneity of HH through its putative peripheral eﬀect on numbers of circulating CD8+ Tc e l l s .
ursodeoxycholic acid (TUDCA) and the short-chain fatty
acid derivate sodium 4-phenylbutyrate (4PBA) are two of
such agents whose value in inhibiting the stress elicited by
the HFE C282Y mutant was already established in vitro
[23]. The former was shown to increase the stability of
the C282Y protein, whereas reduced levels of intracellular
aggregates were achieved by 4PBA supplementation. These
results, underscored by the recently uncovered impact of
ER stress in iron metabolism, may inspire the design of
new approaches for treating HFE-HH, complementing the
current clinical protocols. In this case, however, a thoroughly
balanced chaperone therapy would be required in order to
preserve the beneﬁcial eﬀects rendered by UPR activation,
as those mediated by CRT against iron-generated oxidative
stress [59].
7. Concluding Remarks
Largely propelled by its implication in varied pathological
conditions, interest in understanding the interface between
ER stress and other cellular signaling pathways is growing
considerably. Over the last decades substantial eﬀort to
elucidate the molecular components and mechanistic details
of the UPR canonical cascades was set in motion, with
remarkable insights being achieved including considering
a role for chaperones in therapy. Our work establishing a
connectionbetweentheUPRandtheexpressionofgenesrel-
evant for the regulation of iron metabolism reviewed in the
present paper extends this networking model, highlighting
further the multitasking nature of the UPR. In addition, our
studies of CRT mRNA expression in genetic iron overload
revealed CRT as a possible signiﬁcant chaperone at the
crossroads of UPR and iron homeostasis with a possible
protective eﬀect towards the iron-mediated disease due to its
antioxidative properties (Figure 3).
Altogether, the title chosen, ER stress and iron homeosta-
sis: a new frontier for the UPR, stresses with a few words the
opening of a new promising avenue in UPR and chaperone
research. It is hoped that with time facts will match the
promise of words.
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